Upstream Bio Inc
UPB
70 hedge funds and large institutions have $690M invested in Upstream Bio Inc in 2024 Q4 according to their latest regulatory filings, with 70 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
78.5% more ownership
Funds ownership: 0% → 78.5% (+78%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$160M |
| 2 |
O
OrbiMed
New York
|
+$127M |
| 3 |
DC
Decheng Capital
Menlo Park,
California
|
+$73.4M |
| 4 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$62.6M |
| 5 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$51.3M |
Top Sellers
UPB Hedge Fund Activity: Q4 2024 in Review
70 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Upstream Bio Inc (UPB) for Q4 2024, worth a combined $690M.
Buyers outnumbered sellers: 70 funds opened new UPB positions and 0 closed out — a net gain of 70 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $160M.
- 70 institutional investors held Upstream Bio Inc (UPB) as of Q4 2024, up from 0 in Q3 2024.
- Funds reported $690M of Upstream Bio Inc stock for Q4 2024.
- 70 funds opened new Upstream Bio Inc positions in Q4 2024 and 0 closed out, a net change of +70 holders.
- The largest Upstream Bio Inc buyer in Q4 2024 was Fidelity Investments, an estimated $160M added.
Based on aggregated 13F filings for Q4 2024.